PM8002 in the Treatment of Patients With Advanced Solid Tumors
Malignant Neoplasm

About this trial
This is an interventional treatment trial for Malignant Neoplasm
Eligibility Criteria
Inclusion Criteria: Voluntary participation in clinical study; fully understand the study and sign informed consent voluntarily; willing to follow and able to complete all test procedures; Male or female aged 18 to 75 years; Patients with malignant tumor confirmed by histology or cytology; The toxicity of previous anti-tumor therapy has not been alleviated; Adequate organ function; ECOG score was 0-1; Expected survival >=12 weeks; According to RECIST 1.1 criteria, at least 1 measurable lesion that has not been previously treated locally. Exclusion Criteria: History of severe allergic disease, severe allergy to drugs or known allergy to any component of the drug in this study; Evidence of major coagulopathy or other obvious risk of bleeding; Patients are experiencing a clear interstitial lung disease or non-infectious pneumonia, unless it is caused by local radiotherapy; Patients with uncontrolled brain metastases should be excluded from this clinical trial; Patients ever experienced other active malignant tumors within 5 years prior to the study treatment; Prior allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation; Known history of alcohol abuse, psychotropic drug abuse or drug abuse; Syphilis antibody positive; Patients with active tuberculosis (TB) are excluded; Pregnant or lactating women; Other conditions lead to inappropriate to participate in this study as judged by the investigator.
Sites / Locations
- Shanghai Orient HospitalRecruiting
Arms of the Study
Arm 1
Experimental
PM8002
PM8002 IV every 2 weeks(q2w) or every 3 weeks(q3w)